The Follow Up Study Regarding the Safety and Efficacy of TT-034, a Genetically-Modified Adeno-Associated Virus Designed to Target Hepatitis C in a Study Under Protocol B2801001.
Clinical Trial Grant
Awarded By
Tacere Therapeutics
Start Date
October 1, 2014
End Date
March 25, 2019
Awarded By
Tacere Therapeutics
Start Date
October 1, 2014
End Date
March 25, 2019